Optimal Corticosteroid Therapy Based on Liver Biopsy for Severe Immune-Mediated Hepatitis During Pembrolizumab Treatment: A Case Report
Cureus · 09.03.2026
DOI: 10.7759/cureus.104904 ↗Kurz gefasst
Fallbericht in der Zeitschrift Cureus, erschienen am 09.03.2026. Verfasst von Kotoba Esaki und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Self-Defense Forces Central Hospital, Tokyo, JPN. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Self-Defense Forces Central Hospital, Tokyo, JPN.
- Department of Internal Medicine, Mishuku Hospital, Federation of National Public Service Personnel Mutual Aid Associations, Tokyo, JPN.
- Department of Gastroenterology, Mishuku Hospital, Federation of National Public Service Personnel Mutual Aid Associations, Tokyo, JPN.
- Department of Respiratory Medicine, Mishuku Hospital, Federation of National Public Service Personnel Mutual Aid Associations, Tokyo, JPN.
Zitieren
APA
Esaki, K., Horikoshi, H., Awashima, M., Nakayama, S., & Kichikawa, Y. (2026). Optimal Corticosteroid Therapy Based on Liver Biopsy for Severe Immune-Mediated Hepatitis During Pembrolizumab Treatment: A Case Report. Cureus. https://doi.org/10.7759/cureus.104904
Vancouver
Esaki K, Horikoshi H, Awashima M, Nakayama S, Kichikawa Y. Optimal Corticosteroid Therapy Based on Liver Biopsy for Severe Immune-Mediated Hepatitis During Pembrolizumab Treatment: A Case Report. Cureus. 2026. doi:10.7759/cureus.104904
BibTeX
@article{Esaki2026,
author = {Esaki, Kotoba and Horikoshi, Hideyuki and Awashima, Maiko and Nakayama, Satoshi and Kichikawa, Yoshiko},
title = {Optimal Corticosteroid Therapy Based on Liver Biopsy for Severe Immune-Mediated Hepatitis During Pembrolizumab Treatment: A Case Report},
journal = {Cureus},
year = {2026},
doi = {10.7759/cureus.104904}
}
EUVIMED